Geoffrey Labarque

Differential production of proinflammatory cytokines in the pig lung during different respiratory virus infections: correlations with pathogenicity

Abstract The acute stages of infection with swine influenza virus ( SIV ), porcine respiratory coronavirus ( PRCV ) and porcine reproductive-respiratory syndrome virus ( PRRSV ) were shown to differ in terms of clinical and lung inflammatory effects and proinflammatory cytokine profiles in bronchoalveolar lavage ( BAL ) fluids. Caesarian-derived colostrum-deprived pigs were inoculated intratracheally with one of the three viruses. SIV infection was followed within 1 day post inoculation (d PI ) by characteristic respiratory and general signs, and excessive lung epithelial desquamation and neutrophil infiltration (38 to 56 per cent of BAL cells at 1 d PI vs 0 to 1 per cent in controls). High concentrations of bioactive interferon-α ( IFN -α), tumour necrosis factor-α ( TNF -α) and interleukin-1 ( IL -1) coincided with peak symptoms and neutrophil infiltration. PRCV infection was asymptomatic and produced a mild bronchointerstitial pneumonitis and neutrophil infiltration (13 to 22 per cent of BAL cells at 4 d PI ). IFN -α titres parallelled those found during SIV infection, TNF -α was negligible and IL -1 undetectable. PRRSV infection induced anorexia and lethargy between 3 and 5 d PI . There was marked infiltration with mononuclear cells in alveolar septa and BAL fluids between 7 and 10 d PI , while neutrophils remained at less than 11 per cent of BAL cells at any time. IL -1 was produced from three throughout 10 d PI , while IFN -α production was minimal and TNF -α undetectable. These data strongly suggest that proinflammatory cytokines can be important mediators of viral respiratory disease.

Effect of cellular changes and onset of humoral immunity on the replication of porcine reproductive and respiratory syndrome virus in the lungs of pigs.

Twenty-two 4- to 5-week-old gnotobiotic pigs were intranasally inoculated with 10(6.0) TCID(50) of porcine reproductive and respiratory syndrome virus (PRRSV) (Lelystad) and euthanized at different time intervals post-inoculation (p.i.). Bronchoalveolar lavage (BAL) cell populations were characterized, together with the pattern of virus replication and appearance of antibodies in the lungs. Total BAL cell numbers increased from 140x10(6) at 5 days p.i. to 948x10(6) at 25 days p.i. and remained at high levels until the end of the experiment. The number of monocytes/macrophages, as identified by monoclonal antibodies 74-22-15 and 41D3, increased two- to fivefold between 9 and 52 days p.i. with a maximum at 25 days p.i. Flow cytometry showed that the population of differentiated macrophages was reduced between 9 and 20 days p.i. and that between the same time interval, both 74-22-15-positive and 41D3-negative cells, presumably monocytes, and 74-22-15- and 41D3-double negative cells, presumably non-phagocytes, entered the alveolar spaces. Virus replication was highest at 7 to 9 days p.i., decreased slowly thereafter and was detected until 40 days p.i. Anti-PRRSV antibodies were detected starting at 9 days p.i. but neutralizing antibodies were only demonstrated in one pig euthanized at 35 days and another at 52 days p.i. The decrease of virus replication in the lungs from 9 days p.i. can be attributed to (i) shortage of susceptible differentiated macrophages, (ii) lack of susceptibility of the newly infiltrated monocytes and (iii) appearance of anti-PRRSV antibodies in the lungs. Neutralizing antibodies may contribute to the clearance of PRRSV from the lungs.

Respiratory tract protection upon challenge of pigs vaccinated with attenuated porcine reproductive and respiratory syndrome virus vaccines

In this study, the efficacy of two attenuated porcine reproductive and respiratory syndrome virus (PRRSV) vaccines was assessed. The virological protection in the lungs of vaccinated pigs upon challenge was studied. Also, challenged pigs were exposed to lipopolysaccharide (LPS) to evaluate clinical protection. Six-week-old pigs were immunized intramuscularly with commercial vaccines based on either an attenuated American or an attenuated European virus strain. Non-immunized pigs and pigs intramuscularly inoculated with the virulent Lelystad strain were included as controls. Six weeks after immunization, pigs were challenged either intratracheally or intranasally with the Lelystad strain, and 3 and 6 days later intratracheally exposed to Escherichia coli LPS. After LPS administration, pigs were monitored for clinical signs. At 4 and 7 days after challenge, pigs were euthanized to determine virus quantities in broncho-alveolar lavage (BAL) fluids and in lungs. Challenge virus was recovered from three out of eight pigs that had been primo-inoculated with the Lelystad strain with titers ranging between 0.3 and 3.1 log(10). Fifteen out of sixteen pigs vaccinated with the attenuated American strain were positive for challenge virus and their mean virus titers were similar to those of non-immunized challenge controls. Eleven out of 16 pigs vaccinated with the attenuated European strain were positive for challenge virus and their mean virus titers were 2.0-2.5 log(10) lower than those of non-immunized challenge controls. Thus, the virological protection in the lungs of vaccinated pigs upon challenge was incomplete, but was more pronounced in the homologous situation. Clinical signs upon LPS exposure in both vaccinated groups were not reproducible in two experiments.

Seroprevalence of H1N1, H3N2 and H1N2 influenza viruses in pigs in seven European countries in 2002–2003

Objectives  Avian‐like H1N1 and human‐like H3N2 swine influenza viruses (SIV) have been considered widespread among pigs in Western Europe since the 1980s, and a novel H1N2 reassortant with a human‐like H1 emerged in the mid 1990s. This study, which was part of the EC‐funded ‘European Surveillance Network for Influenza in Pigs 1’, aimed to determine the seroprevalence of the H1N2 virus in different European regions and to compare the relative prevalences of each SIV between regions.

Efficacy of vaccination of pigs with different H1N1 swine influenza viruses using a recent challenge strain and different parameters of protection

This study investigates whether antigenic evolution within H1N1 swine influenza viruses can compromise vaccine efficacy and, specifically, whether the A/New Jersey/8/76 strain in the commercial swine influenza vaccines needs to be updated. Pigs were vaccinated twice intramuscularly with experimental monovalent vaccines derived from different H1N1 strains (A/New Jersey/8/76, Sw/Belgium/1/83 or Sw/Belgium/1/98) or with a commercial bivalent vaccine based on A/New Jersey/8/76 (H1N1) and A/Port Chalmers/1/73 (H3N2). Experimental and commercial vaccines contained a different adjuvant. Two weeks after the second vaccination, all pigs were challenged intratracheally with Sw/Belgium/1/98. Mean pre-challenge haemagglutination inhibition (HI) antibody titres against the challenge virus were lower for the experimental A/New Jersey/8/76 vaccine than for the other vaccines. The reduction in mean virus titres in the lungs was highly significant for the latter vaccines, including the commercial New Jersey-derived vaccine, but not for the experimental A/New Jersey/8/76 vaccine. Clinical signs after challenge were negligible in all vaccinates. Post-challenge levels of interferon-alpha and tumor necrosis factor-alpha in bronchoalveolar lavage fluids were reduced in the vaccinates, while levels of interleukin-1 and neutrophils were less consistent. Though the A/New Jersey/8/76 strain is less effective in preventing infection by Sw/Belgium/1/98 than the homologous virus or than Sw/Belgium/1/83, all strains can protect completely if antibody titres against the challenge virus are sufficiently high. Apart from the vaccine strain, adjuvant and antigenic dose may play a crucial role in vaccine efficacy.

Seroprevalence of porcine circovirus types 1 and 2 in the Belgian pig population.

Two immunoperoxidase monolayer assays (IPMA) were used to examine some epidemiological aspects of porcine circovirus (PCV) type 1 and 2 infections in the Belgian pig population. Both tests were validated using antisera raised after experimental inoculation with PCV type 1 or 2 of caesarean-derived colostrum-deprived pigs. Infection with PCV type 1 resulted in antibodies which also showed cross-reaction with PCV type 2 but homologous titres were 4-fold higher than heterologous ones. Infection with PCV type 2 resulted in antibodies which reacted only with PCV type 2 and not with PCV type 1. Pooled serum samples from nursery pigs, fattening pigs, and young sows, collected in Belgium between 1985 and 1996, were tested for antibodies against PCV type 1 and 2, using both tests. Antibodies against PCV type 1 and 2 were demonstrated in 95 and 100% of the herds respectively. Paired serum samples from pigs at 4 and 14 weeks of age were also tested. The pigs were from five breeding-fattening herds and samples were collected between 1996 and 1998. Almost every pig seroconverted between 4 and 14 weeks of age against PCV type 2 in all five herds tested, whereas seroconversion against PCV type 1 was rather irregular. Seroconversion against PCV type 2 did not coincide with a clinical picture typical for the postweaning multisystemic wasting syndrome (PMWS). These studies indicate that PCV type 2 infections occur systematically in pigs and that other factors, such as management, housing, and/or concurrent viral-bacterial infections, are probably necessary in order to induce the wasting syndrome.

The combination of PRRS virus and bacterial endotoxin as a model for multifactorial respiratory disease in pigs

Abstract This paper reviews in vivo studies on the interaction between porcine reproductive and respiratory syndrome virus (PRRSV) and LPS performed in the authors’ laboratory. The main aim was to develop a reproducible model to study the pathogenesis of PRRSV-induced multifactorial respiratory disease. The central hypothesis was that respiratory disease results from an overproduction of proinflammatory cytokines in the lungs. In a first series of studies, PRRSV was shown to be a poor inducer of TNF-α and IFN-α in the lungs, whereas IL-1 and the anti-inflammatory cytokine IL-10 were produced consistently during infection. We then set up a dual inoculation model in which pigs were inoculated intratracheally with PRRSV and 3–14 days later with LPS. PRRSV-infected pigs developed acute respiratory signs for 12–24h upon intratracheal LPS inoculation, in contrast to pigs inoculated with PRRSV or LPS only. Moreover, peak TNF-α, IL-1 and IL-6 titers were 10–100 times higher in PRRSV–LPS inoculated pigs than in the singly inoculated pigs and the cytokine overproduction was associated with disease. To further prove the role of proinflammatory cytokines, we studied the effect of pentoxifylline, a known inhibitor of TNF-α and IL-1, on PRRSV–LPS induced cytokine production and disease. The clinical effects of two non-steroidal anti-inflammatory drugs (NSAIDs), meloxicam and flunixin meglumine, were also examined. Pentoxifylline, but not the NSAIDs, significantly reduced fever and respiratory signs from 2 to 6h after LPS. The levels of TNF-α and IL-1 in the lungs of pentoxifylline-treated pigs were moderately reduced, but were still 26 and 3.5-fold higher than in pigs inoculated with PRRSV or LPS only. This indicates that pathways other than inhibition of cytokine production contributed to the clinical improvement. Finally, we studied a mechanism by which PRRSV may sensitize the lungs for LPS. We hypothesized that PRRSV would increase the amount of LPS receptor complex in the lungs leading to LPS sensitisation. Both CD14 and LPS-binding protein, two components of this complex, increased significantly during infection and the amount of CD14 in particular was correlated with LPS sensitisation. The increase of CD14 was mainly due to infiltration of strongly CD14-positive monocytes in the lungs. The PRRSV–LPS combination proved to be a simple and reproducible experimental model for multifactorial respiratory disease in pigs. To what extent the interaction between PRRSV and LPS contributes to the development of complex respiratory disease is still a matter of debate.

Porcine reproductive-respiratory syndrome virus infection predisposes pigs for respiratory signs upon exposure to bacterial lipopolysaccharide

Abstract This study examined whether an infection with porcine reproductive and respiratory syndrome virus (PRRSV) potentiates respiratory signs upon exposure to bacterial lipopolysaccharides (LPS). Five-week-old conventional pigs were inoculated intratracheally with the Lelystad strain of PRRSV and received 5 days later one or two intratracheal LPS administrations. The necessary controls were included. After LPS administration, pigs were intensively monitored for clinical signs. Additionally, some pigs were euthanatized after a second LPS administration for broncho-alveolar cell analysis and virological examinations of the lungs. Broncho-alveolar lavage (BAL) cells were counted and differentiated. Lung suspensions and BAL fluids were titrated for PRRSV. Exposure of pigs to PRRSV only resulted in a fever for time periods ranging from 1 to 5 days and slight respiratory signs. Exposure of pigs to LPS only resulted in general signs, characterized by fever and depression, but respiratory signs were slight or absent. PRRSV–LPS exposed pigs, on the other hand, developed severe respiratory signs upon LPS exposure, characterized by tachypnoea, abdominal breathing and dyspnoea. Besides respiratory signs, these pigs also showed enhanced general signs, such as fever and depression. Lung neutrophil infiltration was similar in non-infected and PRRSV-infected pigs upon LPS exposure. PRRSV quantities were similar in lungs and BAL fluids of pigs infected with PRRSV only and PRRSV–LPS exposed pigs. These data show a clear synergism between PRRSV and LPS in the induction of respiratory signs in conventional pigs. The synergism was observed in 87% of the pigs. So, it can be considered as reproducible and may be used to test the efficacy of preventive and therapeutic measures.

Performance of a Commercial Swine Influenza Virus H1N1 and H3N2 Antibody Enzyme-Linked Immunosorbent Assay in Pigs Experimentally Infected with European Influenza Viruses

The IDEXX Swine influenza virus H1N1 and H3N2 enzyme-linked immunosorbent assays (ELISAs) are used worldwide, but their capacity to detect antibodies to European Swine influenza viruses (SIVs) has not been documented. A total of 313 well-defined sera from SIV seronegative pigs and pigs experimentally infected with European SIVs were used to compare the performance of both ELISAs and the hemagglutination inhibition (HI) test. The ELISAs largely failed to detect pigs that had been infected with H1N1 (0/42 positive in H1N1 ELISA) or H3N2 only (9/18 positive in H3N2 ELISA; group 1). Higher ELISA detection rates were found after consecutive infection of pigs with either H1N1 or H3N2 and 1 other subtype (7/40 and 11/22 positive in H1N1 and H3N2 ELISA, respectively; group 2). Of 39 pigs that had been vaccinated twice with 1 of 4 commercial SIV vaccines (group 3), 25 tested positive in the H1N1 and 4 in the H3N2 ELISA. Pigs that had received a single vaccination after a prior infection with H1N1 and/or H3N2 (group 4) were more frequently positive than group 1 or 3 pigs (23/24 and 15/24 positive in H1N1 and H3N2 ELISA, respectively). Both the H1N1 and H3N2 ELISA showed a low sensitivity (39% and 35%, respectively) relative to the HI test. Because pigs in the field are frequently infected and/or vaccinated with multiple SIV subtypes and variants, they are more likely to test positive in the ELISAs. However, the interpretation of ELISA results will be difficult, and HI remains the method of choice.

Apoptosis in the Lungs of Pigs During an Infection with a European Strain of Porcine Reproductive and Respiratory Syndrome Virus

It has been shown, in vitro, that porcine reproductive and respiratory syndrome virus (PRRSV) induces apoptosis during its replication in both MA-104 cells and porcine alveolar macrophages (Suarez et al., 1996). Since transfection of mammalian cells with ORF5 of PRRSV leads to apoptosis it was suggested that the 25-kDa glycosylated membrane protein GP5 of PRRSV is responsible for this phenomenon. Apoptosis has also been demonstrated in vivo with North-American strains of PRRSV (Sur et al, 1997, 1998; Sirinarumitr et al., 1998). Apoptotic cells were localized in germinal epithelial cells of testicles (Sur et al, 1997), in lungs and in lymphoid tissues of pigs (Sirinarumitr et al., 1998; Sur et al., 1998). The apoptotic cells were morphologically recognized as alveolar and pulmonary intravascular macrophages and mononuclear cells in the alveolar septa in lungs and as macrophages and mononuclear cells in lymph nodes. Apoptotic cells were more abundant than PRRSV-infected cells in all tissues and double-labeling experiments indicated that the majority of apoptotic cells were uninfected bystander cells.